The story was also silent about costs, did not include an independent perspective, and pulled a quote from a press release from the American Academy of Neurology. Had it covered the topic more thoroughly, this story would probably have been less confused as to why so many patients choose not to prevent headaches merely “by swallowing a few pills.” The issue is far more complex than that.
Migraine headaches can be debilitating and can last from hours to days per episode. Although a great deal of emphasis has been placed on their treatment, prevention has been a poor stepchild. Only about a third of people who suffer from migraines have frequent enough or severe enough episodes to warrant the risks associated with preventive treatments. But as we know from the article in Neurology, only a small minority of those who could benefit actually do so. The reasons are likely multiple and include a lack of understanding on the part of the patient or caregiver, economics or side effects to name a few.
The cost of migraine prevention drugs was not mentioned and cost is an important consideration. The costs range from pennies a day for beta blockers to over $300 for a monthly regimen of Trova. Even the guideline authors mentioned cost as a potential barrier.
Here’s what the story states: “Neurologists estimate that about 38% of people who suffer from migraines stand to benefit with such a regimen, and studies suggest that as many as half of migraines can be prevented with drugs.”
Thanks to the competing USA Today coverage, we know that this is an overly optimistic assessment, since in that story it was noted that patients may need to try 3 or 4 different drugs, alternative therapies, and lifestyle changes to achieve a 50% reduction in headaches.
Although the story was not specific enough on this point, it reminded readers that all drugs “can have side effects or interact with other medications.” It didn’t mention how serious they might be or how often they might occur. We’ll give the story the benefit of the doubt however since the list of drugs is long and the incidence and severity of the side effects is complicated
There is no discussion of how these ratings were developed. There is also no mention of limitations of the studies that formed the basis for the guidelines. The guidelines themselves note, for example, that migraine prevention studies were usually of short duration (often only 12–16 weeks), and so the long-term efficacy of these therapies is uncertain.
The story noted that 5 of the 6 guideline authors disclosed relationships with drug companies. However, the only source quoted in the article is one of the guideline authors — no independent perspective was included.
Unlike the USA Today story we reviewed, non-drug approaches were not mentioned. Despite the fact that the story was based on a set of guidelines for drug treatments, we would have liked to have seen a few words on non-pharmacologic approaches including stress reduction, diet, etc.
It’s clear from the story that these drugs are widely available.
The story did not oversell the novelty of these drugs.
We can’t be sure of the extent to which the story relied on a news release. We do know:
Systematic, Criteria-Driven
We’ve written about the hype of liquid biopsies for years (see link in comment below). And now this…. https://www.statnews.com/2022/01/12/medicare-shouldnt-cover-liquid-biopsies-early-cancer-detection/
Case counts still matter. “(There) are stories that may not be told adequately if only hospitalizations and deaths are emphasized.” @garyschwitzer interviewed by @dbauder of @AP. https://apnews.com/article/omicron-changing-news-outlets-covid-data-da9272f7c4c8a109c3bfb56bed9e9c76
My friend Gary @garyschwitzer wrote to his city council representative in a Minnesota town about a Viva Las Vegas event scheduled for January.
The response he got seems to perfectly capture where we are now.
https://www.healthnewsreview.org/2021/12/2021-ends-with-covid-craziness-in-sports-and-politics/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like